SCHEMBL4014749

SCHEMBL4014749

Cc1c2c(=O)n(CC(F)CNC(=O)OC(C)(C)C)c3cc4c(cc3c2nn1C(=O)OC(C)(C)C)CCCC4

nearest known ligand 0.33

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 4/20 0.33
KCNH2 Q12809 1/20 0.33
DYRK1A Q13627 1/20 0.32
LMNA P02545 2/20 0.31
MAPT P10636 2/20 0.31
HPGD P15428 2/20 0.31
HSD17B10 Q99714 2/20 0.31
KDM4E B2RXH2 1/20 0.31
GLA P06280 1/20 0.31
GAA P10253 1/20 0.31
CASP1 P29466 1/20 0.31
RAB9A P51151 1/20 0.31
CASP7 P55210 1/20 0.31
ALDH1A1 P00352 1/20 0.30
ALOX15 P16050 1/20 0.30
TSHR P16473 1/20 0.30
MAPK1 P28482 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
GPR119 Q8TDV5 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4017813 1.00 CHEK1 (0.33) CHEK1KCNH2DYRK1ALMNAMAPT
SCHEMBL4023100 1.00 CHEK1 (0.33) CHEK1KCNH2DYRK1ALMNAMAPT
SCHEMBL4019355 0.86 PTGDR2 (0.35) LMNAMAPTKDM4ERAB9ATSHR
SCHEMBL4017815 0.84 CHEK1 (0.50) CHEK1KCNH2DYRK1ALMNAMAPT
SCHEMBL5132256 0.81 CHEK1 (0.33) CHEK1RAB9AGPR119
SCHEMBL5128333 0.77 PTGDR2 (0.35) LMNAMAPTKDM4ERAB9ATSHR
SCHEMBL5132632 0.74 CHEK1 (0.46) CHEK1KCNH2DYRK1ALMNAHSD17B10
SCHEMBL5129516 0.71 CNR2 (0.41) DYRK1A
SCHEMBL4005010 0.71 DYRK1A (0.46) DYRK1A
SCHEMBL6508712 0.66 ATR (0.36) KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7550477-B2 Inhibitors of checkpoint kinases MERCK & CO., INC. (US) 2009-06-23 US disclosed
US-7550477-B2 Inhibitors of checkpoint kinases MERCK & CO., INC. (US) 2009-06-23 US disclosed
US-20090023767-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2009-01-22 US disclosed
US-20090023767-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2009-01-22 US disclosed
EP-1976523-A2 INHIBITORS OF CHECKPOINT KINASES Merck & Co., Inc. (US) 2008-10-08 EP disclosed
WO-2007081572-A2 INHIBITORS OF CHECKPOINT KINASES MERCK & CO., INC. (US) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023767-A1 Inhibitors of Checkpoint Kinases CHEK1, CHEK2, BUB1B CHEK1 1/4885KCNH2 2921/4885DYRK1A 734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.